Objectives: The current standard of practice for evaluation of myelodysplastic syndromes (MDS) includes peripheral blood and bone marrow morphology review and conventional karyotyping. Karyotype provides a global view of the chromosome complement while fluorescence in situ hybridization (FISH) targets specific abnormalities. The aim of this study was to determine if an MDS-FISH panel would add value beyond karyotype in MDS workup.
The myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis that leads to varying cytopenias and a maturational dysplasia in one or more of the myeloid cell lines. Patients with MDS are ultimately at risk for either progression to acute myeloid leukemia (AML) or morbidity related to bone marrow failure. The World Health Organization has classified MDS into categories based on the percentage of blasts and the type of dysplastic maturation. 1 Various recurring cytogenetic abnormalities in patients with MDS have prognostic importance and have been included in MDS prognostic algorithms. 1, 2 Currently, the minimal standard practice for evaluating patients with a clinical or morphologic suspicion for MDS is morphologic assessment of the peripheral blood and bone marrow together with conventional karyotype analysis. In addition, it is not uncommon to see concurrent order of fluorescence in situ hybridization (FISH) studies that target regions associated with recurring MDS-related chromosome abnormalities.
This clinical practice is likely to change as there has been a rapid growth of knowledge from next-generation sequencing studies that have identified a multitude of gene mutations in the myeloid malignancies that may be associated with overall survival, disease progression, and potential novel targeted therapy choice. [3] [4] [5] [6] [7] [8] [9] [10] [11] The ability to identify these genetic anomalies is likely to come into direct conflict with both health care payers, who have historically been slow to reimburse new technology, and health care reform proposals, such as accountable care organizations, both of whom will be looking for value-based, efficient ways (ie, less testing) to care for patients. The challenge for the clinical hematology and hematopathology practices will be how to incorporate the most meaningful genetic studies in the care of the hematology patient that will either directly determine the therapy chosen or provide sufficient prognostic information that will drive a particular course of treatment. As these new genetic assays become more widely available, hematologists and hematopathologists will need to avoid testing that either is redundant or provides little incremental value to the care of that patient.
With this as background, the purpose of this study was to determine if FISH analysis provides any additional diagnostic, prognostic, or therapeutic value beyond conventional karyotype studies in evaluating the patient with possible MDS. Our unique and ultimate goal was to devise an effective and efficient approach of cytogenetic test utilization in MDS workup.
Materials and Methods
This research project was reviewed and approved by the Mayo Clinic Institutional Review Board. We identified Mayo Clinic patients being evaluated for a possible MDS who were seen between January 2007 and June 2012. All patients were seen by a Mayo Clinic Rochester hematologist. Clinical review of the patient's medical record and bone marrow aspiration and biopsy were done on all patients. The diagnosis was based on hematopathology review of the peripheral blood, bone marrow, and pertinent laboratory results, including hemoglobin level, leukocyte count, platelet count, absolute neutrophil count, and karyotype findings.
Conventional karyotyping and FISH testing using a panel of MDS-associated probes were performed on all the study patients by the Mayo Clinic Cytogenetics Laboratory. Only those patients tested with at least five probes from the MDS-FISH panel were included Table 1 .
Chromosome analysis was performed on fresh bone marrow aspirate samples. The specimens were cultured and harvested following standard cytogenetic methods, and chromosome preparations were stained using GTL banding with trypsin and Leishman stain. FISH analysis was performed using commercial or laboratory-developed probes that were previously validated. A total of 500 nuclei were scored for dual-color, dual-fusion FISH probes designed to identify translocations or inversions (eg, MECOM/RUNX1, RPN1/MECOM) and 200 nuclei for probes detecting copy number changes (eg, þ8), deletions (eg, 5q-), or breakapart probes detecting gene disruptions (eg, KMT2A, also known as MLL). FISH analyses were independently evaluated by two technologists.
For each bone marrow specimen, metaphases were analyzed and karyotyped and the total numbers of abnormal and normal cells recorded. The FISH probes used for each specimen and the percentage of abnormal nuclei identified with each probe were also documented. Chromosome results were classified as normal, nonclonal, and abnormal based on standard international-derived criteria. 12 Specimens were considered normal (eg, nonneoplastic) if no abnormality was detected; the only abnormality was a loss of a sex chromosome, a balanced constitutional rearrangement, or samples with trisomy 15. 13, 14 An abnormality was considered nonclonal when fewer than two metaphases with a chromosome gain or structural rearrangement or fewer than three cells with a chromosome loss were identified. Cases with a nonclonal karyotype result were included in the normal karyotype category. The karyotype study was considered adequate when 20 or more metaphases were available for review and insufficient when only one to 19 metaphases were identified.
Results
From January 2007 through June 2012, 505 patients with suspected or diagnosed MDS who had a bone marrow evaluation and concurrent conventional karyotype and MDS-FISH testing were identified. The patients ranged in age from 3 to 94 years (median, 68 years); 320 were males and 185 were females. Of the patients, 437 were anemic (hemoglobin range, 5.9-16.6 g/dL; median, 9.9 g/dL), 196 were neutropenic (neutrophils range, 0.01-63.4 Â 10 9 /L; median, 2.0 Â 10 9 /L), and 345 were thrombocytopenic (platelet range, 1-1,368 Â 10 9 /L; median, 89 Â 10 9 /L). Pancytopenia was observed in 144 patients.
Karyotyping was successfully performed on 501 (99%) of 505 patients, and the other four cases had no metaphase cells available for karyotypic analysis. Karyotyping studies were adequate with 20 or more metaphases analyzed in 462 (92.2%) of 501 patients and insufficient in 39 (7.8%) of 501 cases with fewer than 20 metaphases available for analysis. 
Cases With Adequate Karyotyping
In total, 324 patients with a normal karyotype had concordant normal MDS-FISH results, and 95 patients with an abnormal karyotype also demonstrated concordant abnormal MDS-FISH results ( Table 2) .
Fourteen patients had a normal karyotype but abnormal MDS-FISH results. Two patients carried nonclonal karyotypic abnormalities that were confirmed by FISH studies Table 4 . The other 12 cases included seven patients with MDS, one with CMML, two with AML, and two negative for myeloid neoplasm (Table 4 ). Both patients negative for myeloid neoplasm carried a diagnosis of plasma cell myeloma, and the detected FISH abnormalities most likely reflect findings in the neoplastic plasma cells. It is well known that the neoplastic plasma cells divide poorly in conventional karyotyping culture conditions, and targeted plasma cell FISH is routinely used to detect these chromosome abnormalities, with the discordance between the two methods as expected. In the remaining 10 cases (seven with MDS, one with CMML, and two with AML), the discrepancy between karyotyping and MDS-FISH findings did not alter the diagnosis in any case. However, the additional FISH findings did upgrade the cytogenetic prognostic scoring in three patients with MDS by the Revised International Prognostic Scoring System for MDS 2 and one patient with CMML by both the Spanish CMML-Specific Prognostic Scoring System (CPSS) 15 and Global MD Anderson Prognostic Scoring System (G-MDAPS). 16 They included 7q-(18%), RUNX1 loss (65%) and MECOM amplification (14%, 4-10 copies), MECOM gain (25.6%, three copies), and 7q-(15%) in these four cases, respectively, all observed in 15% or more of interphase nuclei (Table 4 ). In the other four MDS cases, low-level FISH abnormalities (3%-10.5%) of þ8 and 20q-; þ3, þ8, and þ13; þ8, 20q-, and MECOM gain; and þ3 and þ5 were detected, respectively. These low-level FISH findings are of uncertain clinical significance and did not warrant an alteration of the cytogenetic prognostic scoring. In the two AML cases, the FISH abnormalities of þ8 and RUNX1 gain at a very low level (2%-5%) had no impact on the cytogenetic prognostic scoring of AML. Normal karyotype includes nonclonal results. Nonclonal is defined as fewer than two metaphases with a chromosome gain or structural rearrangement or fewer than three cells with a chromosome loss. Twenty-nine patients showed karyotypic abnormalities but normal MDS-FISH results. The karyotypic abnormalities identified were not targeted by the MDS-FISH panel in 22 cases. In the remaining seven cases, including three patients with MDS, one with MDS/MPN, and three without myeloid neoplasm, the MDS-FISH panel performed did target the karyotypic abnormalities ( Table 4 ). The karyotypic abnormalities detected in these seven cases were all present at low levels, ranging from two (5%) of 38 to three (15%) of 20 metaphases in patients with myeloid neoplasms and three (8%) of 40 to two (10%) of 20 metaphases in the nonmyeloid neoplasm cases, respectively. The discordance between the two methods had no impact on the diagnosis/interpretation of the cases or the cytogenetic prognostic scoring in the four patients with myeloid neoplasms.
Cases With Insufficient Karyotype Analysis
In 39 of 501 cases, fewer than 20 metaphase cells were available for analysis, with 17 cases having 11 to 19 metaphases and 22 cases with 1 to 10 metaphases. Overall, 26 of 39 cases had a normal karyotype and normal MDS-FISH results, and seven of 39 cases had an abnormal karyotype and abnormal MDS-FISH findings Table 5 . In five patients (four with MDS and one with CMML), the abnormal karyotype and MDS-FISH results were concordant. The two patients demonstrating discordance were both negative for a myeloid neoplasm and carried a diagnosis of B-lymphoblastic leukemia/lymphoma (B-LBL). One had a 47,XX,þ14[13]/48,idem,þ8[1]/46,XX [4] karyotype, and the MDS-FISH confirmed the þ8 but showed an additional finding of 5q-at 10%. The other patient with B-LBL had a complex karyotype, and the MDS-FISH revealed a low-level 20q-(8.5%). In both cases, the lowlevel additional MDS-FISH findings are of uncertain clinical significance. In addition, four of 39 cases exhibited normal karyotype/abnormal FISH results, including two patients with MDS, one with AML, and one negative for myeloid neoplasm (Table 5 ). FISH abnormalities detected in the two patients with MDS included one case with 5q-(55%) and 7q-(45%) and the other with 7q-(10%). The other two cases showed a low-level þ8 (3%) in the AML case and 20q-(6%) in the case negative for myeloid neoplasm. Last, two of 39 cases had abnormal karyotypes and normal MDS-FISH results ( Table 5 ). The MDS-FISH probes targeted the karyotypic abnormalities in the MDS case showing add(3)(q21) but not in the other case negative for myeloid neoplasm.
Overall, in the 39 cases with insufficient karyotype analysis, the discordant cases included the two patients with B-LBL from the abnormal karyotype/abnormal FISH subgroup, all four patients from the normal karyotype/abnormal FISH subgroup, and one patient from the abnormal karyotype/normal FISH subgroup. The discordant rate was 18% (7/39). The discrepancy had no impact on the diagnoses, and the additional FISH abnormalities identified in the four normal karyotype/abnormal FISH and two abnormal karyotype/abnormal FISH cases altered cytogenetic prognostic scoring in two patients with MDS ( Table 5) . As there were 20 myeloid neoplasm cases in this insufficient karyotyping group (Table 3) , the rate of cytogenetic prognostic scoring impact by FISH was 10% (2/20).
Discussion
There is an emerging challenge between how today's practice of medicine is financed in the United States and the explosive growth in molecular genetic technology related to our understanding of hematologic diseases. Resource utilization has become an increasingly prominent focus of health care reform as proposals such as accountable care organizations offer bundled payments with incentives based on value and patient outcomes rather than the number of services provided. Thus, both laboratories and clinical practices will be under increasing pressure to reduce utilization of expensive testing unless it provides benefits to patient outcomes. The challenge facing hematology and hematopathology will be how to incorporate these new technologies and new genetic and molecular findings while financially justifying them as part of a quality patient care paradigm.
If an evidence-based approach is used to address these utilization questions, then this conflict between health care cost and the growth in molecular and scientific knowledge could be minimized and might help us evolve to a more effective and efficient practice of medicine. A clinically relevant yet financially prudent approach will be essential if we are to incorporate this explosion of new scientific knowledge into clinical practice. Making the distinction between what is needed for diagnostic purposes vs what prognostic information is needed to offer appropriate therapy or clinical counseling will need to be balanced with scientific discovery and medical advancements, especially if bundled payments in oncology practices become the standard.
Our study is an important step in addressing this important issue. The role of genetic studies in the evaluation of the patient with MDS has been widely affirmed, with virtually all classification systems relying on cytogenetic studies for stratifying patients into good to poor prognostic categories. 2, [16] [17] [18] [19] [20] [21] The discovery of lenalidomide as an effective treatment in patients with a del(5q) abnormality has further cemented the role of genetic studies in the diagnosis and treatment of the patient with MDS. [22] [23] [24] [25] Recent studies in MDS have shown frequent somatic mutations in the spliceosomal machinery (eg, SFB31, SRSF2, U2AF1, ZRSR2), epigenetic modifiers (eg, TET2, DNMT3A, IDH2/1, EZH2, ASXL1), signaling transducer, transcription factors, and other important gene targets (eg, RUNX1, TP53, NRAS, STAG2, CBL, ETV6). [3] [4] [5] [6] [7] [8] This molecular information has exhibited value in refining the MDS prognostic risk stratification scheme and may improve therapy response prediction and choice of potential targeted therapies. 10, 11, [26] [27] [28] [29] [30] [31] Understanding the role of FISH as a genetic tool is important when developing a test utilization process. FISH's most useful role is in detecting interphase abnormalities in cells that do not divide in typical karyotyping culture conditions. Chronic lymphocytic leukemia and plasma cell neoplasms are the best-known examples of this phenomenon. The use of FISH when no fresh tissue is available (use of paraffin-embedded tissue) or when a bone marrow procedure is to be avoided (ie, use of peripheral blood) has extended the study of cytogenetics outside that of a fresh marrow specimen. FISH can also detect cryptic abnormalities that are below the recognition level of chromosome banding studies. Examples of this latter situation include the detection of a PDGFRA rearrangement using CHIC2 as a surrogate marker in myeloid and lymphoid neoplasms with PDGFRA rearrangement commonly presenting with hypereosinophilia and identification of the commonly cryptic t(12;21)(p13;q22), ETV6-RUNX1 (TEL/AML1) fusion by FISH as a prognostic marker in pediatric B-LBL.
Because of these scenarios where FISH will detect abnormalities that are not recognized by conventional karyotype studies, it has been extrapolated that FISH studies in general offer a much improved sensitivity over routine karyotyping studies in detecting deletions, duplications, and translocations. This conclusion has not been based on data and has led to the increasing practice of doing MDS-FISH studies in practically all cases of potential MDS. However, it is important to recognize that MDS is a myeloid stem cell disorder with all myeloid cell lineages capable of dividing in vitro and thus likely to be detected by metaphase chromosome analysis (ie, karyotyping). A core piece of knowledge that is frequently overlooked is that the cutoffs for positivity for most FISH probes, including those used in this study, are usually around 5%. Although comparing different cell preparations, this percentage is comparable to the detection limit in chromosome studies where clonality is defined as two abnormal metaphases out of 20 (ie, 10% of cells). Thus, it should not be surprising that the detection rate is comparable between these two methods.
The results from our study support this assumption and showed that MDS-FISH studies provide little additional value beyond conventional karyotype studies if that study is adequate (defined by at least 20 metaphases available for analysis). In our study cohort of 462 patients with adequate 32 Mayo plus ASXL1 prognostic model, 33 or the Groupe Francophone Des Myelodysplasies CMML model 34 were used, then the additional FISH finding of 7qwould not have affected the CMML prognostic scoring, and the FISH impact rate drops to 1.5% (3/206). These findings are in contrast to those cases that had insufficient karyotype analysis (<20 metaphases), which showed a lower concordance rate (82.1%, 32/39) and higher FISH myeloid neoplasm cytogenetic prognostic scoring impact rate (10%, 2/20). The observed higher discordance rate and FISH impact rate in this group are not surprising as the analytic performance of the karyotype analysis in these cases was compromised by its insufficient nature, most commonly attributable to inadequate or hemodilute samples. In these scenarios, supplemental utilization of a MDS-FISH panel is warranted to improve the sensitivity and accuracy of detection of the recurrent MDS-related chromosome abnormalities and confirm ambiguous karyotypic findings in patients with possible MDS.
Detection of a del(5q) is important in identifying those patients with MDS who may benefit from lenalidomide therapy. Thus, the use of MDS-FISH for del(5q) detection in particular has been rationalized on the basis of offering these patients a viable and effective therapeutic alternative. However, it is important to note that in our study, MDS-FISH did not identify any cases of del(5q) that were not identified or suspected by karyotype analysis when 20 or more metaphase cells were analyzed ( Table 4) .
The results from our study and the conclusions reached are consistent with other previously published reports in MDS assessment, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] although some earlier studies were not as comprehensive as the current study, included fewer patients, generally used fewer FISH probes, or based the comparison of the two methods regardless of the number of metaphase cells analyzed, whereas the results from our study clearly point out the necessity of using that information in the decision-making process. Interestingly, our findings in MDS are also similar to those reported in many cases of the diagnostic workup for AML, where adequate FISH was found to rarely provide any additional information with adequate karyotype analysis. [45] [46] [47] [48] [49] On the basis of the combination of our findings, national/international guidelines, 50, 51 and evidence from other published scientific literature, we propose a value-based cost-effective diagnostic algorithm for the workup of patients with possible MDS. It begins with a bone marrow and peripheral blood morphologic assessment and conventional karyotyping Figure 1 . If 20 or more metaphase cells are present for analysis, routine use of an MDS-FISH panel is not recommended. However, targeted MDS-FISH using select probes could be done at the discretion of the cytogeneticist to clarify ambiguous chromosome abnormalities revealed by chromosome analysis such as possible breakpoints and to confirm nonclonal MDS-associated abnormalities. When fewer than 20 metaphase cells are available, MDS-FISH studies should be performed to increase the sensitivity and accuracy of detecting recurring MDS-related chromosome abnormalities.
In conclusion, our study demonstrated limited value of MDS-FISH in working up of possible MDS cases when the conventional karyotype analysis is adequate. As the current health care system is under increasing pressure to provide value-based services and cut down on unnecessary medical expenditure, we propose a value-based, cost-effective algorithm that provides essential diagnostic and prognostic cytogenetic information and reduces unnecessary and redundant testing. This algorithm of MDS workup separates our study from many others and serves as a paradigm of value-based optimization of complex laboratory test utilization, whose significance is not limited to laboratory medicine but also applicable to multiple other medical disciplines.
